Safety profile of mycophenolate mofetil: a response
Drs Basara and Fauser's thoughful and insightful comments 1 reinforce what we have documented in our report, namely that mycophenolate mofetil (MMF) can be safely used for the treatment of chronic GVHD with few sideeffects occurring in a minority of the patients. 2 In our study, adverse gastrointestinal events including diarrhea, nausea and vomiting were the most common clinically relevant side-effects, occurring in 30% (five out of 15) of the patients, whereas severe liver toxicity occurred in one case. Nevertheless, it should be emphasized that MMF was discontinued in only two patients (13%) due to the presence of adverse reactions.
The frequency of gastrointestinal side-effects in our series was higher than the data already reported by the studies of Basara et al 3 and Mookerjee et al 4 indicating 16% and 19% incidence of gastrointestinal symptoms, respectively. Due to the small number of patients our data must be carefully evaluated with no over-interpretation. However, it is worth recalling that our results refer to the use of MMF in a cohort of pediatric patients (in this respect, the age of the five patients who experienced gastrointestinal symptoms varied from 5 to 8 years). This fact might be relevant because the compliance as well as the tolerability and the safety profile of MMF may be different in children compared with the adults.
In accordance with these speculations, we report our experience in 16 adult patients with hematological malignancies who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) and received MMF as prophylaxis (n = 8) or treatment of chronic GVHD (n = 8). Only two patients (12%) experienced adverse gastrointestinal events and therapy was withheld temporarily in one case; MMF was restarted after the resolution of symptoms with no subsequent recurrence of the side-effect. No liver or hematological toxicities have been observed in this small series of patients.
Furthermore, Basara and coworkers have argued that organ involvement by severe GVHD (gastrointestinal tract, liver) and adverse effects of MMF may be overlapping, thereby making difficult any meaningful evaluation of the toxicity profile of the drug. As stated in the discussion, we hypothesized that the patient who showed severe liver toxicity might have chronic GVHD with hepatic involvement (as suggested by histological evaluation of the liver) and this fact might in turn have predisposed to liver abnormalities. This clinical situation seems to be very similar to that depicted by Basara and colleagues. 3 In conclusion, our data have documented a favorable toxicity profile of MMF, even though clinicians should be aware that children might have a higher incidence of adverse events with gastrointestinal symptoms predominating. Additional studies are needed to differentiate the sideeffects of MMF from the clinical signs of severe GVHD.
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